INmune Bio (NASDAQ:INMB) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.47) by 8.51 percent. This is a 29.51 percent increase over losses of $(0.61) per share from the same period last year. The company reported $50.00 thousand in sales this quarter. This is a 257.14 percent increase over sales of $14.00 thousand the same period last year.